Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Prostate cancer

A closer look at the initial results from the REDUCE trial

Nature Reviews Urology volume 7, pages 535–537 (2010)Cite this article

Subjects

Initial results of the REDUCE trial suggest that dutasteride decreases the incidence of prostate cancer in men with persistently elevated PSA; however, questions have emerged about the drug's effect on the incidence of high-grade cancer. Adjustment for post-randomization confounders, however, brings the true benefit of this drug into clearer focus.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Attempts to adjust for the effect of dutasteride on serum PSA in clinical trials can introduce important biases.

References

  1. Andriole, G. L. et al. Effect of dutasteride on the risk of prostate cancer. N. Engl. J. Med. 362, 1192–1202 (2010).

    Article  CAS  Google Scholar 

  2. Thompson, I. M. et al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349, 215–224 (2003).

    Article  CAS  Google Scholar 

  3. Fleshner, N. E., O'Sullivan, M. & Fair, W. R. Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J. Urol. 158, 505–508 (1997).

    Article  CAS  PubMed  Google Scholar 

  4. Cohen, Y. C. et al. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. J. Natl Cancer Inst. 99, 1366–1374 (2007).

    Article  CAS  PubMed  Google Scholar 

  5. Pinsky, P., Parnes, H. & Ford L. Estimating rates of true high-grade disease in the prostate cancer prevention trial. Cancer Prev. Res. 1, 182–186 (2008).

    Article  Google Scholar 

  6. Redman, M. W. et al. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev. Res. 1, 174–181 (2008).

    Article  CAS  Google Scholar 

  7. Choo, R. et al. How much does Gleason grade of follow-up biopsy differ from that of initial biopsy in untreated, Gleason score 4–7, clinically localized prostate cancer? Prostate 67, 1614–1620 (2007).

    Article  CAS  PubMed  Google Scholar 

  8. Kramer, B. S. et al. Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J. Clin. Oncol. 27, 1502–1516 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, University of Illinois at Chicago, 840 South Wood Street, Chicago, 60612, IL, USA

    Peter H. Gann

Authors
  1. Peter H. Gann
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gann, P. A closer look at the initial results from the REDUCE trial. Nat Rev Urol 7, 535–537 (2010). https://doi.org/10.1038/nrurol.2010.144

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2010.144

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing